Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

NGR-hTNF: Interim Phase II data

June 3, 2013 7:00 AM UTC

Interim data from 55 evaluable patients in the open-label, European Phase II Study NGR016 trial showed that weekly IV infusions of 0.8 µg/m 2 NGR-hTNF in combination with doxorubicin (Arm C) met the p...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article